| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. Generic abiraterone and prednisolone for newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) is being considered for suitability for AWMSG assessment, interim to the outcome of the NICE review of TA721, by the AWMSG Scrutiny Panel at their meeting on 09/01/2025. |
|
Medicine details |
|
| Medicine name | abiraterone acetate (Zytiga®) |
| Formulation | 250 mg and 500 mg tablet |
| Reference number | 2043 |
| Indication | Treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/11/2017 |
| NICE guidance | |
| Further information Generic abiraterone and prednisolone for newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) is being considered for suitability for AWMSG assessment interim to the outcome of the NICE review of TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer by the AWMSG Scrutiny Panel at their meeting on 09/01/2025. |
|